Eli Lilly and Company v. Actavis Elizabeth
435 F. App'x 917
Fed. Cir.2011Background
- Defendants filed ANDAs with Paragraph IV certifications challenging the validity and enforceability of Lilly's ’590 patent on atomoxetine for treating ADHD.
- The district court sustained the ’590 patent against inequitable conduct, anticipation, obviousness, and non-enablement, but found lack of utility/enablement invalidity.
- The patent discloses using tomoxetine to treat ADHD, with Claim 1 covering administering an effective amount to treat ADHD.
- Clinical data and human trials followed filing; FDA approved tomoxetine for ADHD in adults and children, and the drug achieved wide use.
- Issues centered on obviousness, enablement/utility, and infringement theories, including inducement and contributory infringement based on FDA-labeled ADHD use.
- On appeal, the Federal Circuit reversed certain aspects (invalidity for lack of enablement/utility) and affirmed others (infringement and most validity findings), remanding for further proceedings.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Obviousness of the patent claims | Lilly argues atomoxetine would be obvious for ADHD given norepinephrine inhibition. | Defendants contend prior art shows atomoxetine would be obvious to test for ADHD use. | No reversible error; claims not invalid for obviousness. |
| Enablement/scope of claim 1 | Specification fails to enable full scope beyond exemplified formulations. | Formulations and dosages are routine; skilled persons can determine them without undue experimentation. | Enablement found; district court erred in invalidating on this basis. |
| Enablement/utility under §101 | Utility for ADHD is disclosed and supported by the specification; human data not required at filing. | Lack of human efficacy data in the specification undermines utility. | Utility adequately disclosed and enabled; no lack of enablement/utility. |
| Inducement and contributory infringement | Labeling and distribution of ADHD-use atomoxetine may induce infringement. | Provision of a labeled product for a patented use cannot infringe when use is directed by label. | Inducement established; district court erred in contributory infringement ruling; liability for inducement remains. |
Key Cases Cited
- KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007) (reaffirmed flexible, common-sense approach to obviousness under 35 U.S.C. §103)
- Janssen Pharmaceutica N.V. v. Teva Pharmaceuticals USA, Inc., 583 F.3d 1317 (Fed. Cir. 2009) (enablement must be present when correlating activity to therapeutic use)
- In re Brana, 51 F.3d 1566 (Fed. Cir. 1995) (utility disclosures must be credible; burden shifts if PTO initially questions utility)
- In re Marzocchi, 439 F.2d 220 (CCPA 1971) (first paragraph of §112 enablement depends on truth of utility statements)
- DSU Med. Corp. v. JMS Co. Ltd., 471 F.3d 1293 (Fed. Cir. 2006) (induced infringement focus under labeling that encourages infringing use)
- AstraZeneca LP v. Apotex, Inc., 633 F.3d 1042 (Fed. Cir. 2010) (inducement/infringement analysis where label-directed use implies infringement)